Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA1 Mutation”

285 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 285 results

Not applicableLooking for participantsNCT05378204
What this trial is testing

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Institut Claudius Regaud 120
Not applicableStudy completedNCT03471572
What this trial is testing

Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India

Who this might be right for
Ovarian Cancer
AstraZeneca 240
Testing effectiveness (Phase 2)Looking for participantsNCT04090567
What this trial is testing

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Who this might be right for
Advanced Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+12 more
M.D. Anderson Cancer Center 60
Testing effectiveness (Phase 2)UnknownNCT00080756
What this trial is testing

Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease

Who this might be right for
brca1 Mutation Carrierbrca2 Mutation CarrierBreast Cancer
City of Hope Medical Center 11
Not applicableEnded earlyNCT01103128
What this trial is testing

Validation of a Mouse Model of Pancreatic Carcinogenesis

Who this might be right for
Pancreatic Cancer
Columbia University 450
Testing effectiveness (Phase 2)Study completedNCT01898312
What this trial is testing

BRCA1/2 and Effect of Mifepristone on the Breast

Who this might be right for
Women With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2
Karolinska Institutet 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT02571725
What this trial is testing

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms
New Mexico Cancer Research Alliance 50
Testing effectiveness (Phase 2)Study completedNCT01078662
What this trial is testing

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Who this might be right for
OvarianBreastProstate+2 more
AstraZeneca 298
Not applicableUnknownNCT04983628
What this trial is testing

Molecular Profiling in Prostate Cancer

Who this might be right for
Prostate Cancer MetastaticProstate Cancer RecurrentGermline BRCA1 Gene Mutation+2 more
Hellenic Cooperative Oncology Group 250
Not applicableStudy completedNCT04823871
What this trial is testing

Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing

Who this might be right for
Ovarian Epithelial CancerCarcinoma in SituOvarian Cancer
Paul Speiser, Prof.MD, 406
Not applicableStudy completedNCT05305001
What this trial is testing

Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico

Who this might be right for
Pancreatic CancerPancreatic Adenocarcinoma
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 107
Testing effectiveness (Phase 2)Active Not RecruitingNCT05498272
What this trial is testing

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

Who this might be right for
Prostate CancerBRCA1 MutationBRCA2 Mutation+2 more
Rana McKay, MD 32
Not applicableActive Not RecruitingNCT03546972
What this trial is testing

Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants

Who this might be right for
Deleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationDuctal Breast Carcinoma In Situ+3 more
M.D. Anderson Cancer Center 51
Testing effectiveness (Phase 2)Ended earlyNCT03499353
What this trial is testing

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Who this might be right for
Early Breast Cancer
Pfizer 61
Large-scale testing (Phase 3)Looking for participantsNCT06380751
What this trial is testing

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
AstraZeneca 788
Testing effectiveness (Phase 2)WithdrawnNCT01661868
What this trial is testing

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Who this might be right for
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Dana-Farber Cancer Institute
Early research (Phase 1)Ended earlyNCT05252390
What this trial is testing

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorOvarian CancerOvary Cancer+24 more
Nuvation Bio Inc. 82
Early research (Phase 1)Study completedNCT01154426
What this trial is testing

ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

Who this might be right for
Adult Solid NeoplasmBRCA1 Mutation CarrierBRCA2 Mutation Carrier
National Cancer Institute (NCI) 31
Large-scale testing (Phase 3)Study completedNCT02282020
What this trial is testing

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 266
Early research (Phase 1)Study completedNCT04991480
What this trial is testing

ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced CancerMetastatic CancerBreast Cancer
Artios Pharma Ltd 93
Next Page